|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-1-23
|
|
pubmed:abstractText |
Many patients with rheumatoid arthritis are currently successfully treated with infliximab (anti-tumour necrosis factor); however, about 30% of the patients do not respond to infliximab. One of the postulated hypotheses of not responding is the fast clearance of infliximab due to the development of infliximab-anti-infliximab complexes.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-11096166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-12584368,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-15485995,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-15647331,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-16508927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-18714521,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-4544996,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-52321,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-8229241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-8546736,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-9406684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16793840-9751087
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0003-4967
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
253-6
|
|
pubmed:dateRevised |
2010-9-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16793840-Adult,
pubmed-meshheading:16793840-Aged,
pubmed-meshheading:16793840-Antibodies, Monoclonal,
pubmed-meshheading:16793840-Antigen-Antibody Complex,
pubmed-meshheading:16793840-Antirheumatic Agents,
pubmed-meshheading:16793840-Arthritis, Rheumatoid,
pubmed-meshheading:16793840-Autoantibodies,
pubmed-meshheading:16793840-Female,
pubmed-meshheading:16793840-Humans,
pubmed-meshheading:16793840-Immunosuppressive Agents,
pubmed-meshheading:16793840-Isotope Labeling,
pubmed-meshheading:16793840-Joints,
pubmed-meshheading:16793840-Liver,
pubmed-meshheading:16793840-Male,
pubmed-meshheading:16793840-Metabolic Clearance Rate,
pubmed-meshheading:16793840-Middle Aged,
pubmed-meshheading:16793840-Spleen,
pubmed-meshheading:16793840-Technetium,
pubmed-meshheading:16793840-Treatment Failure,
pubmed-meshheading:16793840-Whole Body Imaging
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis.
|
|
pubmed:affiliation |
Department of Rheumatology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. j.vanderlaken@vumc.nl
|
|
pubmed:publicationType |
Journal Article
|
